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frequently harbour ATRX mutations 
Olivera Casar-Borota
1,2
, Henning Bünsow Boldt
3,4
, Britt Edén Engström
5,6
















, Jens Otto L Jørgensen
18





, Åse Krogh Rasmussen
23
, John R Lindsay
24,25




































Department of Clinical Pathology, Uppsala University Hospital, Uppsala, Sweden 
3 
Department of Pathology, Odense University Hospital, Odense, Denmark 
4 
Department of Clinical Research, University of Southern Denmark, Odense, Denmark 
5
Department of Medical Sciences, Endocrinology and Mineral Metabolism, Uppsala University, 
Uppsala, Sweden 
6
Department of Endocrinology and Diabetology, Uppsala University Hospital, Uppsala, Sweden 
7
Department of Endocrinology, Odense University Hospital, Odense, Denmark, 
8
Clinical Institute, University of Southern Denmark, Odense, Denmark 
9
Department of Neurosurgery, Foch Hospital, Suresnes, France 
10
Department of Internal Medicine, Kalmar, Region of Kalmar County, Sweden 
11
Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden 
12






















Department of Endocrinology, Karolinska University hospital, Stockholm, Sweden 
14
Department of Endocrinology, University Hospital, Linköping, Sweden 
15
Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden 
16
Department of Medical Endocrinology and Metabolism, Rigshospitalet, Copenhagen, Denmark 
17
Institute of Clinical Medicine, Faculty of Health Research Sciences, Copenhagen University, 
Copenhagen, Denmark 
18
Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark 
19
Section of Specialized Endocrinology, Department of Endocrinology, Oslo University Hospital, 
Oslo, Norway 
20
Faculty of Medicine, University of Oslo, Oslo, Norway 
21
Centre for Endocrinology, William Harvey Research Institute, Barts, UK 
22
The London School of Medicine and Dentistry, Queen Mary University of London, London, UK 
23
Department of Endocrinology and Metabolism, Copenhagen University Hospital, Copenhagen, 
Denmark 
24
Mater Infirmorum Hospital, Belfast Health & Social Care Trust (BHSCT), UK 
25
Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast Health & Social 
Care Trust, UK 
26
Patrick G Johnston Centre for Cancer Research, Queen’s University, Belfast, UK 
27
Department of Endocrinology and Nutrition, UCL Cliniques universitaires Saint-Luc, 1200 
Brussels, Belgium 
28






















University of Oslo (UiO) and Oslo University Hospital (OUS), Department of Pathology, 
Translational Neurodegeneration Research and Neuropathology Lab, Oslo, Norway 
30
LIED, University of Lübeck, Lübeck, Germany 
31
Department of Pharmacology, Medical Faculty, University of Latvia, Riga, Latvia 
32
Pathology Unit, Department of Molecular and Translational Medicine, University of Brescia 
Medical School, Brescia, Italy 
33
Medical Faculty, University of Belgrade, Serbia 
34
Department of Internal Medicine and Clinical Nutrition, Institute of Medicine at Sahlgrenska 
Academy, University of Gothenburg, Gothenburg, Sweden  
35
Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg, Sweden 
36
Endocrinology, Abdominal Center, Helsinki University Hospital and University of Helsinki, 
Helsinki, Finland 
37
Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmar 
38
Department of Internal Medicine and Oncology, Faculty of Medicine, Semmelweis University, 
Budapest, Hungary 
39
Department of Pathological Cytology and Anatomy, Foch Hospital, Suresnes, France  
40
INSERM U1016, Institut Cochin, Paris, France; Université Paris Descartes-Université de Paris, 
Paris, France 
41
Department of Endocrinology, Sart Tilman B35, 4000 Liège, Belgium 
42
Department of Neurosurgery, Maria Sklodowska-Curie National Research Institute of Oncology, 
Warsaw, Poland 
43






















Olivera Casar-Borota, M.D., Ph.D., Associate Professor 
Department of Immunology, Genetics and Pathology, Uppsala University and Department of Clinical 
Pathology, Uppsala University Hospital, Uppsala, Sweden 
Dag Hammarskjölds väg 20 





Grants and fellowships supporting the writing of the paper: Olivera Casar-Borota was supported 
by the Swedish Cancer Society (grant number 190157 Fk) and by the grant from the Swedish state 
under the agreement between the Swedish government and the county councils (ALF-agreement). 
Henning B. Boldt was supported by the Region of Southern Denmark. Camilla Schalin-Jäntti received 
funding from the Helsinki University Hospital Research Funds (TYH2018223, TYH20191254). Pia 
Burman received a research grant from Skåne University Hospital, Region of Skåne, Sweden. 
 






















Context: Aggressive pituitary tumours (APTs) are characterised by unusually rapid growth and lack 
of response to standard treatment. About 1-2% develop metastases being classified as pituitary 
carcinomas (PCs). For unknown reasons, the corticotroph tumours are overrepresented amongst APTs 
and PCs. Mutations in the ATRX gene, regulating chromatin remodelling and telomere maintenance, 
have been implicated in the development of several cancer types, including neuroendocrine tumours.  
Objective: To study ATRX protein expression and mutational status of the ATRX gene in APTs and 
PCs. 
Design: We investigated ATRX protein expression by using immunohistochemistry in 30 APTs and 
18 PCs, mostly of Pit-1 and T-Pit cell lineage. In tumours lacking ATRX immunolabeling,  
mutational status of the ATRX gene was explored.  
Results: Nine of the 48 tumours (19%) demonstrated lack of ATRX immunolabelling with a higher 
proportion in patients with PCs (5/18 - 28%) than in those with APTs (4/30 – 13%). Lack of ATRX 
was most common in the corticotroph tumours, 7/22 (32%), vs 2/24 (8%) in the tumours of the Pit-1 
lineage. Loss-of-function ATRX mutations were found in all the nine ATRX immuno-negative cases: 
nonsense mutations (n=4), frameshift deletions (n=4) and large deletions affecting 22-28 of the 36 
exons (n=3). More than one ATRX gene defect was identified in two PCs.  
Conclusion: ATRX mutations occur in a subset of aggressive pituitary tumours and are more 
common in corticotroph tumours. The findings provide a rationale for performing ATRX 
immunohisto hemistry to identify patients at risk of developing aggressive and potentially metastatic 
pituitary tumours.  
Keywords: ATRX (alpha thalassemia/mental retardation syndrome X-linked); aggressive PitNETs; 























Pituitary neuroendocrine tumours (PitNETs) (1), traditionally designated as pituitary 
adenomas, are usually benign tumours with indolent, non-aggressive course. Recently, the 
European Society of Endocrinology published criteria that define aggressive PitNETs as 
tumours demonstrating an unusually fast growth and/or lack of response to all standard 
treatment modalities including surgery, radio- and pharmacological therapies (2). Pituitary 
carcinomas (PC) are defined by the presence of non-contiguous craniospinal or distant 
metastases (3). While PC are rare and comprise only 0.1-0.2% of all pituitary neoplasms (4), 
the prevalence of aggressive pituitary tumours (APT) without metastases is less well known. 
An estimate of 3% has been suggested based on indices of increased proliferation and 
extensive p53 staining in tumour specimens from 451 patients reported to the German 
Pituitary Tumour Registry (5). Little is known about genetic abnormalities driving invasive 
and metastatic pituitary tumours. Whether they develop through malignant progression of 
benign pituitary tumours or occur as de novo malignant tumours caused by early, single or 
multiple genetic changes predisposing for distant dissemination is unknown. 
The functioning corticotroph tumours causing Cushing´s disease represent less than 5% of the 
benign, slow-growing PitNETs (6,7). However, they are overrepresented amongst APT and 
PC where they constitute approximately 30-40% (8,9). One suggested explanation for this 
was a lower expression of the cell cycle inhibitor p27 in normal corticotroph cells and 
corticotroph tumours (10); however, the mechanisms are still unclear. Silent corticotroph 
tumours are also considered potentially more aggressive according to the current World 
Health Organisation (WHO) classification of the pituitary tumours (3), although a recent 
meta-analysis could not identify an increased recurrence rate in this subtype (11). 
In patients with aggressive pituitary tumours, genetic abnormalities have previously only 





















patients (12). In a case of clinically non-functioning gonadotroph carcinoma, a low level of 
HER2/neu gene amplification was demonstrated by using FISH and CISH analysis (13). The 
presence of mi-RNAs probably targeting PTEN (phosphatase and tensin homolog) and 
TIMP2 (tissue inhibitor of metalloproteinases 2) was reported as potential drivers of 
metastatic growth in a case with a non-functioning PC (14). A single case of PC was reported 
in a patient with succinate dehydrogenase subunit B gene mutation and history of 
paraganglioma (15). Finally, tumour protein p53 mutations in two PC have been described 
(16). 
ATRX interacts with death domain-associated protein (DAXX) and the histone H3.3 variant in 
heterochromatin remodelling and maintenance of telomere structure and function (17,18). 
Inactivation of ATRX or, less frequently DAXX in ATRX/DAXX mutated tumours, leads to 
telomere destabilisation and facilitates the process of alternative lengthening of telomeres (ALT), 
which results in cancer cell immortality (19,20). Somatic ATRX gene mutations are associated with 
several different tumour types, including astrocytomas in adults (21) and neuroendocrine tumours 
(NET) such as pancreatic NETs (22,23), neuroblastomas (24) and 
paragangliomas/pheochromocytomas (25,26). Interestingly, in neuroendocrine tumours, ATRX 
abnormalities seem to predict malignant tumour phenotype, being present in high grade malignant 
tumours such as neuroblastoma (24), or associated with poor prognosis and/or metastatic potential, 
such as in pancreatic NET (27), and pheochromocytomas/paraganglioma (26).  
We have previously demonstrated normal immunohistochemical expression of ATRX protein in a 
large cohort of 246 well-characterised PitNETs localised to the sellar region, including 37 
corticotroph tumours. However, one of two studied pituitary carcinomas (a corticotroph carcinoma in 























In the present study, we aimed to further explore ATRX protein expression and mutational status of 
the ATRX gene in a large cohort of aggressive PitNETs and pituitary carcinomas.   
Material and methods 
Patient cohort 
Pituitary tumour specimens were obtained from a multicentre cohort of 48 patients (15 F, 33 M), with 
a median age 45 (range 16-73 years) at diagnosis. Inclusion criteria were at least one pituitary surgery 
and tumour progression despite radiotherapy, and/or while on treatment with dopamine agonists or 
somatostatin analogues, or metastatic disease. Thirty patients had APT and 18 had PC with 
cerebrospinal and/or systemic metastases. The median time from diagnosis of the pituitary tumour to 
metastases was 8.5 (range 1.2 - 36) years (Table 1). The patients were treated at specialised centres in 
11 European countries (Belgium, Denmark, Finland, France, Hungary, Italy, Norway, Poland, Serbia, 
Sweden and UK). Patients’ data and tumour characteristics at the first presentation, treatments given, 
and outcome were collected in anonymised standardised questionnaires filled in by all participating 
centres.  
Information on pituitary tumour size and local extension at the first magnetic resonance imaging 
(MRI) was available in 45 and 43 patients, respectively. All but one lactotroph tumour were 
macroadenomas at the time of diagnosis. By the time of pituitary surgery, invasion of the cavernous 
sinuses, bone and/or brain was evident on MRI in the 39 cases, including the single patient who had a 
microadenoma. Of the 48 patients, 39 had more than one pituitary surgery, and 33 more than two. 
Forty-six out of the 48 patients had received at least one radiotherapy. In one case, tumour size and 
extension were considered too large for radiotherapy, and in the second case, the reason for not 
performing radiotherapy was not available. No tumour treated with dopamine agonists and/or 
somatostatin analogues (octreotide, lanreotide, pasireotide) was controlled by these medications 
(Table 1). In addition to standardised medical therapy, 34 patients had received treatment with 
chemotherapy, temozolomide in 33 including one patient with additional bevacizumab, and another 





















Tumours were classified based on the laboratory and clinical signs of pituitary hormone 
hypersecretion, expression of anterior pituitary hormones in the tumour cells, and, in the cases of 
hormone-negative non-functioning tumours, by their expression of pituitary specific transcription 
factors. Corticotroph tumours were the most common, 22/48, of which 16 were functioning tumours 
causing Cushing’s disease. Lactotroph tumours were the second most common, n=15 (Table 1).       
The index patient with ATRX mutation has been previously reported (28) and is also included in the 
present study. Of the 48 patients, three had syndromes predisposing for pituitary tumours, one had 
MEN1 (29), one had Lynch syndrome (30), and one patient belonged to a kindred with familial 
predisposition for pituitary tumours (FIPA), however, without MEN1 or AIP mutation. In addition, 
pituitary tumour tissue from a corticotroph non-aggressive macroadenoma in a patient with Lynch 
syndrome was investigated. This case was not included in the statistical analyses as it did not fulfil 
criteria for aggressive tumours.  
In 45 patients, at least one specimen from pituitary surgery was available for analyses. In the 
remaining three patients, there was only specimen from the metastasis. For seven patients with 
carcinoma, material from both pituitary surgery and from metastatic tumour was available. The 
presence of representative tumour tissue was confirmed in haematoxylin-eosin stained slides from all 
specimens. 
Immunohistochemical analyses 
Immunohistochemistry (IHC) with antibodies towards growth hormone (GH), prolactin (PRL), 
thyrotroph hormone (TSH), adrenocorticotroph hormone (ACTH), gonadotroph hormones, follicle-
stimulating hormone (FSH) and luteinising hormone (LH), was performed at the local IHC 
laboratories according to the routine protocols. Immunohistochemical analysis with antibodies 
towards pituitary-specific transcription factors was performed at Uppsala University Hospital by using 
anti-SF1 antibody (Abcam, ab217317), anti-Pit-1 antibody (Novus Biologicals, NBP1-92273), and 





















ATRX protein expression was studied on whole sections from formalin fixed paraffin embedded 
tissue blocks. For the patients operated more than once, available tissue specimens from multiple 
surgeries were examined. In the majority of cases, IHC was performed at Uppsala University Hospital 
in a DAKO-Autostainer Link 48 with heat-induced epitope retrieval at high pH. Purified polyclonal 
anti-ATRX antibody (HPA001906, Atlas Antibodies; dilution 1:100; incubation time 20 min) was 
used. Specimens from two adult astrocytomas, one with ATRX mutation and one without ATRX 
mutation, both confirmed by using molecular genetic analysis, were used as negative and positive 
controls. In addition, immunolabelled endothelial cells served as an internal positive control. Four 
cases from Foch Hospital (Suresnes, France) and a case from University Hospital in Copenhagen, 
Denmark were stained in Ventana Benchmark by using the same antibody and according to the locally 
optimised protocols.  
 
Molecular genetic analysis 
Molecular genetic analysis was performed on tumour tissue from the pituitary specimen in all nine 
cases demonstrating lack of ATRX immunolabelling. In two patients, specimens from metastases 
were also analysed. If there was more than one specimen from the pituitary surgery, the specimen 
with the most representative tumour tissue was used. In one patient, a partial lack of ATRX protein 
labelling was observed in the pituitary specimen and a total lack in metastatic tumour tissue. In this 
patient, an attempt was made to microdissect tissue and extract DNA separately from ATRX negative 
and positive area of the pituitary tumour. In addition, the specimen from metastasis with negative 
ATRX staining was analysed.  
All but one specimen were examined by a next generation sequencing panel targeting 20 genes (31) 
related to cancers of the central nervous system as in the initial study (28). Proportion of tumour cells 























Next generation sequencing (NGS) 
DNA was purified from 10 µm paraffin slides using GeneRead DNA FFPE Kit (Qiagen, Germany) 
according to the manufacturer’s instructions. NGS was performed with a custom designed central 
nervous system (CNS) panel covering the entire coding sequence or hotspot regions of 20 genes 
frequently mutated in brain tumors (32). DNA was quantified using an RNase P TaqMan Copy 
Number Reference Assay performed on a QuantStudio 12K Flex Real-Time PCR System (Applied 
Biosystems, Foster City, CA). Libraries were prepared in two primer pools using the Ion AmpliSeq 
Library Kit Plus and Ion Xpress Barcode Adapters 1–96 Kit in 10 µL reaction volume with 5 ng 
template DNA. Library quantitation was performed using the Ion Library Quantitation Kit. Sample 
preparation, chip loading and sequencing were performed using Ion Chef and Ion Torrent S5 System 
with Ion S5 Chef solutions, Ion S5 sequencing reagents and Ion 530/540 Chip Kits. All Ion products 
were supplied by Ion Torrent/ThermoFisher Scientific, Carlsbad, CA, USA. Data analysis, including 
base calling, quality scoring, trimming, demultiplexing, and alignment, was performed using standard 
Ion Torrent Suite v5.10 workflows. BAM alignment files were manually analysed for alterations in 
the coding sequences of the twenty genes using Golden Helix GenomeBrowse 3.0 (Golden Helix, 
Bozeman, MT, USA). The sequencing experiments included ATRX wild-type control samples from 
healthy donors. 
 
























The study has been approved by Regional Ethical Committee in Uppsala (Dnr 2018/327).  
 
Results  
Lack of ATRX protein expression is frequent in corticotroph tumours  
Nine of the 48 tumours (19%) demonstrated lack of ATRX immunolabelling in the tumour cells. Five 
were carcinomas and seven were corticotroph tumours, representing 32% of all corticotroph tumours 
(7 out of 22). Lack of protein expression was more common in patients with functioning corticotroph 
tumours, 6/16 (38%) than in those with silent corticotroph tumours (1/6, 17%). Of the remaining two 
ATRX-immunonegative tumours, one was a lactotroph APT with a fatal outcome, and one was a 
somato-lactotroph carcinoma that initially presented as a prolactinoma and subsequently evolved into 
acromegaly (Table 2).  
More than one pituitary specimen was available for analysis in six of seven patients who underwent  
multiple surgeries. In five of the six patients, all specimens demonstrated lack of ATRX in all tumour 
cells. In one patient, the specimen from the first surgery could not be assessed, there was partial lack 
of ATRX expression in pituitary tumour from the second surgery and a total lack in the metastasis. In 
five patients with PC, specimens from metastases were available in four and demonstrated negative 
ATRX staining in the tumour cells. The remaining 39 pituitary tumours demonstrated intact nuclear 
ATRX expression. 
Examples of PitNETs with normal ATRX staining, total lack of immunolabelling and partial negative 






















All ATRX-immunonegative tumours harbour loss-of-function ATRX gene abnormalities 
ATRX loss-of-function gene abnormalities were found in all nine ATRX-immunonegative tumours  
(Table 3) (31). Two different, damaging ATRX mutations with large differences in mutation 
frequencies were identified in the same primary tumour in two carcinomas from male patients. One of 
these two tumours demonstrated a partial lack of ATRX at IHC. An attempt to extract separately 
DNA from ATRX-immunopositive and negative fraction was, however, unsuccessful, as the same 
mutational status was confirmed in both fractions. Interestingly, only the predominant mutation from 
this pituitary tumour was present in the metastasis (six years later) with a frequency of 98%, 
suggesting clonal heterogeneity and evolution of the primary tumour (Table 3) (31). Three tumours 
did not show any ATRX single nucleotide variants (SNVs) or small indels, but had large, intragenic 
deletions corresponding to most of the coding sequences (22-28 of 36 exons) (Fig. 2A, B). One of 
these tumours was the corticotroph tumour previously reported, whereas the other two were lactotroph 
and somato-lactotroph, respectively. All identified ATRX SNVs and small indels were positioned 
throughout the coding sequence of the ATRX gene (Fig. 2C).  
In addition to the ATRX mutations, eight out of nine ATRX-immunonegative tumours had other 
genetic abnormalities: inactivating somatic mutations in tumour suppressor genes TP53 (six), PTEN 
(two), RB1 (one), NF2 (one), and a homozygous deletion of CDKN2A/B in both primary tumour and 
metastasis in one patient (Table 3). Recurrent CNVs that were estimated from the sequencing data 
were all gains, and involved chromosomes 5, 7, 9p21.3 encompassing CDKN2A/B loci as well as the 
CIC locus on 19q. 
Discussion  
Little is known about genetic abnormalities driving invasive and metastatic growth of PitNETs. Here, 
we demonstrate a loss of ATRX protein expression caused by severe loss-of-function ATRX gene 
alterations in almost a fifth of highly aggressive pituitary tumours, with a higher prevalence in PC 
compared to APT, and in corticotroph tumours compared to other lineage subtypes. This indicates 





















We reported previously normal ATRX expression in 246 PitNETs localised to the sellar region. 
However, in one female patient diagnosed with Cushing’s disease and a pituitary macroadenoma at an 
age of 36 years, we found negative ATRX immunolabelling caused by a large deletion of the ATRX 
gene (28). This tumour had progressed over time and had become metastatic despite multiple 
transsphenoidal surgeries, pharmacological therapy, and three different modalities of radiation 
therapy. ATRX staining was absent in all the tumour specimens including the one from the first 
surgery. 
 
In the present extended study, we demonstrate ATRX gene defects in eight additional patients. Thus, 
nine out of 48 patients (19%) with aggressive pituitary tumours or carcinomas harboured loss-of-
function ATRX gene alterations, more frequently in patients with PC compared to APT (28% vs 
13%). Five out of the total nine patients with ATRX gene defects had carcinomas. Of the four APT 
patients, two died due to progressive tumour growth, in another there was a short time from the 
tumour diagnosis to the study end, and in the last patient, search of metastases was not performed due 
to advanced dementia. Further studies with longer follow-up are needed to assess to what extent an 
initial ATRX defect leads to a metastatic disease.  
 
In addition to our previously reported case of ATRX mutated corticotroph carcinoma (28), a 
corticotroph carcinoma with an ATRX mutation in combination with PTEN and TP53 mutations has 
been described; however, without detailed presentation of genetic data (34).  
In a recent study (35), whole exome sequencing of 18 corticotroph tumours lacking mutations in 
USP8 (ubiquitine specific peptidase 8) gene, mutations that drive corticotroph tumours in 
approximately 50 % of patients with Cushing’s disease, demonstrated ATRX mutations 
concomitantly with TP53 mutations in two. Although detailed clinical data regarding aggressiveness 
of the two ATRX mutated tumours were not presented, both were recurrent and required surgery on 





















(35). Lack of ATRX immunolabelling was recently found in three lactotroph macroadenomas from a 
cohort of 42 paediatric PitNETs, but molecular genetic confirmation of the ATRX mutations was not 
provided (36). Recently, ALT phenotype has been reported in three of 106 PitNETs, two were 
recurrent non-functioning PitNETs without specification of cell-linage differentiation, and one was a 
somatotroph tumour (37). Two of the three ALT-positive PitNETs demonstrated loss of ATRX or 
DAXX at protein level indicating a homozygous loss of the gene or alternative mechanism of gene 
silencing. However, no ATRX or DAXX mutations were identified by sequencing (37). 
In patients who had repeated pituitary surgeries in the present cohort, an ATRX defect was already 
present in the first removed tumour, though, in one patient, tumour tissue from the first surgery was 
not evaluable. This indicates that ATRX abnormalities represent an early genetic event contributing 
to aggressive behaviour and, at least in a subset of patients, to metastatic spread. Where material 
from both the pituitary tumour and metastasis was available (n=4), identical patterns of a complete 
loss of ATRX were seen in three, whereas in one case, partial loss of ATRX was identified in the 
pituitary tumour and a complete loss in the metastasis. A similar case of a PitNET with ALT-
negative phenotype in the original tumour, and ALT-positive phenotype and a partial loss of ATRX 
in a recurrent tumour, was recently reported (37). These findings suggest that an ATRX mutation 
may occur, though rarely, in pituitary tumours with primarily intact ATRX, contributing to malignant 
tumour progression.    
In the ATRX-mutated cases in our cohort, we demonstrated different loss-of-function ATRX defects 
including nonsense mutations, frameshift indels and, in three cases, large, intragenic deletions of 
almost the whole gene (22 to 28 of the 36 exons). Interestingly, large deletions of almost the whole 
ATRX gene have only rarely been reported in other tumour types, such as astrocytomas (21,32), 
pancreatic NETs (22) and pheochromocytomas and paragangliomas (25). Yet, a recent study on 
ATRX alterations in neuroblastoma demonstrated a strong tendency for large, intragenic deletions of 
exons 1-9, encoding the first half portion of the ATRX protein (38). In our cohort, there was no 





















compared to Pit-1-lineage tumours. However, the number of mutated cases may be too low to make 
conclusions on a potential genotype-phenotype association. 
Blood samples or normal tissues from patients were not included in the sequencing experiments to 
test for germline mutations. The variant allele frequencies (VAFs) of mutations in ATRX reported in 
this study are in favour of somatic rather than germline origin. Furthermore, IHC revealed normal 
ATRX expression in non-neoplastic cells in all the mutated specimens, arguing for the somatic origin 
of the ATRX gene defects. 
In the present study, we had the opportunity to investigate ATRX in two patients with 
corticotroph tumours, one non-aggressive macroadenoma and one carcinoma, and Lynch 
syndrome, a cancer predisposing syndrome with mutations in genes involved in DNA 
mismatch repair (MLH1, MSH2, MSH6, PMS2, EPCAM). Both tumours harboured an 
MSH2 mutation, but only the severe case, a carcinoma, in addition exhibited an ATRX 
mutation.  
 
Additional cancer-related mutations were identified and associated with ATRX alterations in 
eight of nine cases, TP53 mutations in six (three aggressive corticotroph tumour, two 
corticotroph carcinomas and one aggressive lactotroph tumour), PTEN mutations in two, and 
RB1, NF2 and CDKN2A/B in single cases. TP53 mutations have rarely been previously 
reported in pituitary tumours (16). However, recently, TP53 mutations were demonstrated in 
six out of 18 of corticotroph USP8 wild-type tumours and correlated with larger tumours and 
higher Ki67 index (35). Our findings, together with  previous report, may suggest an 
association of the TP53 mutations with corticotroph tumours with more aggressive 
phenotype. Findings of multiple mutations in the ATRX mutated tumours may indicate 





















molecular genetic analyses are needed to get full insight into genetic landscape of aggressive 
PitNETs. 
 
The strength of the present study is the well characterised cohort of APT and PC and a relatively large 
number of patients, having in mind the rarity of the condition. A limitation is a short follow up of 
some of the patients with ATRX defects, which limits conclusions on the metastatic potential of this 
mutation.  
Although many APT/carcinomas exhibit histological features consistent with increased proliferation 
(Ki-67 index > 3%, increased mitotic count, and p53 expression) (4), and co-existence of two of the 
three markers is associated with increased risk of tumour progression and recurrence (39), the 
presence of these features does not fully predict future aggressive behaviour (40,41). To our 
knowledge, the present findings is the first time that a gene mutation with well-known oncogenic 
potential has been consistently reported in a proportion of aggressive PitNETs.  
Currently, temozolomide is the first line chemotherapy for APT and PC (29). The drug induces an 
initial response rate of 40%, but subsequently most tumours relapse and long-term effective 
alternative therapies are still lacking (42). Mutated ATRX is an attractive therapeutic target for the 
subgroup of ATRX negative pitui ary tumours. There is ongoing intensive research aiming to develop 
pharmacological therapies targeting ATRX and ALT (43,44).  
In summary, the results of this study provide a rationale for performing ATRX immunohistochemistry 
as a simple, inexpensive and widely available laboratory test to identify patients at increased risk for 
development of highly aggressive and potentially metastatic PitNETs, especially in macroadenomas 
causing Cushing’s disease or in clinically silent corticotroph tumours. Patients with pituitary tumours 
harbouring an ATRX mutation should be offered closer follow-up, including work-up for metastatic 
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Table 1. Patient and tumour characteristics in the study population. 
Table 2. Patient and tumour characteristics in ATRX mutated vs intact cases. 
Table 3. Genetic alterations in ATRX-immunonegative APT and PC by panel NGS. 
Figure 1. Histopathological and immunohistochemical features of PitNETs. Row 1: Haematoxylin 
eosin staining of a primary pituitary tumour invading into the respiratory mucosa (1A) with a total 
lack of ATRX in tumour cells nuclei both the primary pituitary tumour (1B) and a lymph gland 
metastasis (1C) in a patient with a functioning somato-lactotroph carcinoma. ATRX expression is 
intact in respiratory epithelium, endothelial cells and lymphocytes. Row 2: Haematoxylin eosin 
staining from the primary pituitary tumour in a patient with a silent corticotroph carcinoma (2A). A 
partial nuclear ATRX-loss in a proportion of cells in the specimen from the second pituitary surgery 
(2B) and a total ATRX-loss in the metastasis (2C) ATRX expression is preserved in the nuclei of the 
endothelial cells. Row 3: Haematoxylin eosin staining of the specimen from the first surgery (3A) and 
normal ATRX expression in the nuclei of the tumour cells in the specimens from two pituitary 
surgeries (3B, 3C) in a patient with a silent Pit-1 positive PitNET. 
Figure 2. ATRX deletions in two patients with corticotroph carcinoma. A. Profile of the average 
amplicon coverage of ATRX coding sequence from exon 1 through exon 35. A healthy donor of 
female origin was included in all NGS experiments (blue). Low amplicon coverage corresponding to 
deletion of ATRX sequence was observed for two patients, highlighted with orange and green, 
respectively. Coverage overviews are shown as inserts. The black horizontal bar indicates the position 
of chr. X. Arrows mark the deletions in ATRX. B. Schematic illustration of the two large, intragenic 
ATRX deletions spanning exon 2/exon 8 through exon 30. The large exon 9 of ATRX, depicted with 
stippled lines, is compressed for clarity. C. Diagram of ATRX variants at coding and protein levels, 
respectively. Definition of ATRX domains were from UniProt. ADD:  ATRX-DNMT3-DNMT3L. 





















Table 1. Patient and tumour characteristics in the study population 
 Total APT PC 
Total n 48 30 18 
Age at diagnosis, yr 
(median, range) 45 (16-73) 46.5 (18-73) 42 (16-69) 
Male n (%) 33 (69) 23 (77) 10 (56) 
Macroadenomas
a
 44/45 28/29 16/16 
Invasive growth
a
 39/42 24/27 15/15 
No of surgeries 
(median, range) 3 (1-10) 3 (1-10) 3.5 (1-8) 
No of radiotherapies 
(median, range) 1 (0-4) 1 (0-2) 2 (1-4) 
Resistance to DA/ 
somatostatin analogues
b
 27/27 18/18 10/10 
Time to metastases from 1
st
 surgery, 
yr (median, range)   
8.5 (1.2-36) 
Treatment with cytotoxic 
drugs
b
 35/37 21/23 14/14 
ATRX negative, n (%) 9 (19) 4 (13) 5 (28) 
Tumour subtypes (IHC) 
   
- Corticotroph
c
 22 10 12 
- Lactotroph 15 12 3 
- Somatotroph 4 2 2 
- Somato/lactotroph 2 1 1 
- TSH/FSH 1 1 0 
- Silent Pit 1 positive PitNET 3 3 0 
- Null cell 1 1 0 
APT, aggressive pituitary tumours; PC, pituitary carcinoma; DA, dopamine agonists; 
IHC, immunohistochemistry;
 a
MRI at first tumour presentation in patients with available information.
 
b
in patents with available information.
 c

























Table 2. Patient and tumour characteristics in ATRX mutated vs intact cases 
 
  ATRX mutated ATRX intact 
Total n 9 39 
Age at diagnosis, yr (median, range) 45 (23-72) 45 (16-73) 
Male, n (%) 6 (67) 27 (69) 
Aggressive pituitary tumours, n (%) 4 (44) 26 (67) 
Pituitary carcinomas, n (%) 5 (56) 13 (33) 
   
Tumour subtypes (IHC)   
- Corticotroph (n=22) 7 15 
    PC (n=12) 4 8 
    APT (n=10) 3 7 
- Lactotroph (n=15) 1 14 
    PC (n=3) 0 3 
    APT (n=12) 1 11 
- Somato/lactotroph (n=2) 1 1 
    PC (n=1) 1 0 
    APT (n=1) 0 1 
- Other subtypes
a
 (n=9) 0 9 
    PC (n=2) 0 2 
    APT (n=7) 0 7 
IHC, immunohistochemistry; 
a
somatotrophs (4); silent Pit 1 positive (3);  


































Genes Coding Amino Acid 
Freq. 
(%)# 








TP53 c.524G>A p.Arg175His 84 
    




Pituitary loss ATRX c.21_6699del p.E8-K2233del Nu 
    
TP53 c.584T>A p.Ile195Asn 92 










4 Cushing/PC Pituitary loss ATRX c.6679delG p.Asp2227fs 81 
    












    
ATRX c.6661G>T p.Glu2221Ter 31 
    












    
ATRX c.6661G>T p.Glu2221Ter 10 
    










6 Cushing/APT Pituitary loss ATRX c.2422C>T p.Arg808Ter 72 
    
TP53 c.1024C>T p.Arg342Ter 51 
    
PTEN c.697C>T p.Arg233Ter 55 




    
TP53 c.818G>A p.Arg273His 85 
    
NF2 c.1052G>A p.Arg351His 20 




    




























    
CDKN2
A 
c.1_501del p.M1-A167del Ho 
    
CDKN2
B 










    
CDKN2
A 
c.1_501del p.M1-A167del Ho 
    
CDKN2
B 
c.1_414del p.M1-D138del Ho 
APT, aggressive pituitary tumours; PC, pituitary carcinoma; NGS, Next-generation sequencing; ACTH, Adrenocorticotropic 
hormone, GH, growth hormone; PRL, prolactin; #, Estimated ploidy level of larger gene deletions: Nu: nullizygous, He: 
hemizygous deletion, Ho: homozygous deletion; * The same mutations were detected in ATRX immunopositive and 
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